Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 6.6% higher, as traders digest rumors that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was willing to pay over $20 per share to buy the firm. Digging deeper, speculators are expecting ARIA to remain south of $9 in the short term, buying to open the April 9 and May 9 puts. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 5.00% in last session and finished the day at $7.98. Traded volume was 20.70million shares in the last session and the average volume of the stock remained 20.74million shares. The beta of the stock remained 1.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. Idera Pharmaceuticals Inc (NASDAQ:IDRA) rose 17.78 percent to $4.57Friday on volume of 19.70million shares. The intra-day range of the stock was $4.22 to $4.80. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has a market capitalization of $376.39million.

The Shareholders Foundation announces that an investor, who purchased shares of CytRx Corporation (NASDAQ:CYTR), filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by CytRx Corporation (NASDAQ:CYTR) in connection with certain allegedly false and misleading statements made between November 22, 2013 and March 13, 2014. CytRx Corporation (NASDAQ:CYTR)’s stock on Mar 28, 2014 reported a increase of 7.86% to the closing price of $3.43. Its fifty two weeks range is $1.95-$8.35. The total market capitalization recorded $190.59million. The overall volume in the last trading session was 2.20million shares. In its share capital, CYTR has 40.29million outstanding shares.

CORT has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. The stock has moved higher by 31.4% in the past month, while it is also above its 20 Day SMA too. On Friday, shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) advanced 5.44% to close the day at $4.07. Company return on investment (ROI) is -74.10% and its monthly performance is recorded as -1.21%. Corcept Therapeutics Incorporated (NASDAQ:CORT) quarterly revenue growth is 33.01%.